Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 22, 2015

View Archived Issues

TGR-1202 enters phase I trial in solid tumors

Pembrolizumab active in patients with advanced biliary tract cancer

Neurocrine Biosciences begins phase II study of NBI-98854 in Tourette syndrome

Viking Therapeutics performs safety, tolerability and pharmacokinetic study for VK-5211

CXCR4-targeted radiotherapy with [177Lu]/[90Y]pentixather could be useful in multiple myeloma

Foamix initiates phase II trial of FMX-103 in papulopustular rosacea

Yabao Pharmaceutical licenses second diabetes candidate from Lilly

Anti-TNF antibody DLX-105 improves symptoms of Behcet's disease

OPA-15406 shows promise in phase II atopic dermatitis trial

Vitamin B12-PYY3-36 peptide conjugate reduces food intake in vivo

S-76892: a promising agent with procognitive and disease modifier properties

F-17475 is safer and more potent than ketamine in postoperative pain

Bayer Schering Pharma discloses MMP-12 inhibitors

X-Rx patents autotaxin inhibitors

Taisho Pharmaceutical presents orexin receptor antagonists

Syros Pharmaceuticals divulges CDK7 inhibitors

Acquisition and licensing agreements expand Novartis' immune-oncology pipeline

Brighton Biotech acquires license for MERS and SARS vaccines

Pfizer reports IRAK-4 inhibitors

Scancell updates pipeline progress

Biogen reports data from phase III trial of natalizumab in secondary progressive MS

Femtogenix launched to discover anticancer payloads

FDA approves Veltassa for hyperkalemia

AstraZeneca and Lilly expand immuno-oncology combination therapy collaboration

Autoimmune disease candidate ARGX-113 enters phase I trial in healthy volunteers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...